Tilray's aphria rx receives cannabis trading license in germany, significantly expanding commercial growth opportunities

NeumÜnster, germany, july 29, 2024 (globe newswire) -- tilray brands, inc. (“tilray”) (nasdaq: tlry; tsx: tlry), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that aphria rx gmbh (“aphria rx”) has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout germany.
TLRY Ratings Summary
TLRY Quant Ranking